查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957799

2026年全球小干扰核糖核酸（RNA）市场报告

Small Interfering Ribonucleic Acid (RNA) Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，小干扰核糖核酸（RNA）市场发展迅速。预计该市场将从2025年的188.6亿美元成长到2026年的226.9亿美元，年复合成长率（CAGR）达20.3%。过去几年的成长主要归功于分子生物学研究的进步、遗传性和慢性疾病的增加、基于RNA的疗法早期取得的成功、基因组学领域研究经费的增加以及RNA干扰机制的建立。

预计未来几年，小干扰核糖核酸（siRNA）市场将快速成长，到2030年将达到470.7亿美元，复合年增长率（CAGR）为20.0%。预测期内的成长要素包括RNA疗法监管核准的增加、个人化医疗需求的成长、奈米颗粒递送技术的创新、製药公司投资的增加以及siRNA在感染疾病和罕见疾病领域应用的拓展。主要趋势预计包括RNA干扰疗法的临床应用增加、对标靶基因静默技术的日益关注、先进siRNA递送平台的扩展、对精准治疗研发投资的增加以及对可扩展RNA生产的更加重视。

未来几年，对个人化医疗日益增长的需求预计将推动小干扰RNA（siRNA）市场的成长。个人化医疗是一种根据患者的遗传、环境和生活方式因素量身定制治疗方法的医疗策略，旨在改善治疗效果和患者护理。基因组学的进步使得精准识别基因变异并开发针对每位患者的个人化治疗方法成为可能，推动了对个人化医疗的需求成长。小干扰RNA（siRNA）透过达到精准的基因静默来支持个人化医疗，并能有效治疗特定的遗传性疾病。透过选择性抑制致病mRNA，siRNA可以最大限度地减少脱靶效应，提高治疗效果和患者预后。例如，据总部位于美国的非营利组织个人化医疗联盟（PMC）称，截至2024年2月，美国食品药物管理局（FDA）在2023年核准了26种新的个人化药物，高于2022年的12种。因此，对个人化医疗日益增长的需求正在推动小干扰核糖核酸（siRNA）市场的扩张。

在siRNA（小干扰核糖核酸）疗法市场中主要企业正致力于获得监管部门的核准，以开发治疗罕见遗传疾病的创新作用机制，旨在为患者提供持续疗效并最大限度地减少给药频率。监管部门的核准是指相关机构的正式授权，允许安全地对药物或治疗方法进行测试、上市和给药。例如，2025年3月，总部位于美国的生物製药公司Alnilam Pharmaceuticals获得了美国食品药物管理局（FDA）对其产品Qfitlia（fitsiran）的核准。这是首个用于治疗方法，不论患者是否有抑制因子。该疗法旨在透过降低抗凝血酶水平来促进凝血酶的生成，从而支持凝血功能并减少出血事件。 Qfitlia采用皮下注射，每两个月给药一次，为血友病治疗提供了新的非因子疗法选择。

目录

第一章：执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球小型相干核糖核酸（RNA）市场：吸引力分数与分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 人工智慧（AI）和自主人工智慧
    • 工业4.0和智慧製造
    • 数位化、云端运算、巨量资料、网路安全
    • 永续性、气候技术、循环经济
  • 主要趋势
    • RNA干扰疗法的临床应用拓展
    • 人们越来越关注标靶基因静默技术
    • 扩展先进的siRNA递送平台
    • 增加对精准药物研发的投资
    • 加强对可扩展RNA生产的关注。

第五章 终端用户产业市场分析

  • 医院
  • 研究机构
  • 製药公司
  • 生技公司
  • 学术机构

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球小型相干核糖核酸（RNA）市场：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球小型相干核糖核酸（RNA）市场规模、比较及成长率分析
  • 全球小型相干核糖核酸（RNA）市场表现：规模与成长，2020-2025年
  • 全球小型相干核糖核酸 (RNA) 市场预测：规模和成长，2025-2030 年，2035 年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 按类型
  • 脂质体全身疗法、以奈米颗粒为基础的全身疗法
  • 指示
  • 循环系统疾病、呼吸系统疾病、肿瘤、神经退化性疾病、感染疾病
  • 最终用户
  • 医院、研究机构、製药和生物技术公司、学术机构
  • 按类型细分：脂质体全身疗法
  • 阳离子脂质体递送、中性脂质体递送、聚乙二醇化脂质体递送、标靶化脂质体递送
  • 按类型细分：基于奈米颗粒的全身疗法
  • 脂质奈米颗粒递送、聚合物奈米颗粒递送、金奈米颗粒递送、二氧化硅奈米颗粒递送

第十章 区域与国别分析

  • 全球小型相干核糖核酸 (RNA) 市场：按地区划分，历史资料及预测，2020-2025 年、2025-2030 年预测、2035 年预测
  • 全球小型相干核糖核酸 (RNA) 市场：依国家划分，历史资料及预测，2020-2025 年、2025-2030 年预测、2035 年预测

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 小干扰核糖核酸（RNA）市场：竞争格局与市场份额，2024年
  • 小干扰核糖核酸（RNA）市场：公司估值矩阵
  • 小干扰核糖核酸（RNA）市场：公司概况
    • Novartis AG
    • Thermo Fisher Scientific Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Sarepta Therapeutics Inc.

第37章 其他大型企业和创新企业

  • Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年小型相干核糖核酸（RNA）市场：提供新机会的国家
  • 2030年小型相干核糖核酸（RNA）市场：提供新机会的细分市场
  • 2030年小型相干核糖核酸（RNA）市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH5MSIRA02_G26Q1

Small interfering ribonucleic acid (RNA) is a short, double-stranded RNA molecule that is crucial for gene silencing through a mechanism known as RNA interference (RNAi). It attaches to complementary messenger RNA (mRNA) sequences, resulting in their degradation and blocking protein production. The main function of siRNA is to control or reduce the expression of specific genes and is often utilized in research and therapeutic settings to target genes that cause diseases.

The main types of small interfering ribonucleic acid (RNA) include liposome-based systemic therapy and nanoparticle-based systemic therapy. Liposome-based systemic therapy is a drug delivery method that utilizes liposomes to carry therapeutic agents throughout the body via the bloodstream. These therapies are applied for various conditions, including cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, and serve end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

Tariffs are impacting the small interfering ribonucleic acid market by increasing costs of imported nucleotides, lipid nanoparticles, specialized reagents, laboratory instruments, and advanced manufacturing equipment required for siRNA synthesis and delivery. Research institutions and pharmaceutical companies in North America and Europe are most affected due to dependence on imported high-purity raw materials, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising development and production costs and extending clinical timelines. However, they are also encouraging local sourcing of reagents, domestic manufacturing of RNA components, and regional expansion of biopharmaceutical production capabilities.

The small interfering ribonucleic acid (rna) market research report is one of a series of new reports from The Business Research Company that provides small interfering ribonucleic acid (rna) market statistics, including small interfering ribonucleic acid (rna) industry global market size, regional shares, competitors with a small interfering ribonucleic acid (rna) market share, detailed small interfering ribonucleic acid (rna) market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (rna) industry. This small interfering ribonucleic acid (rna) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small interfering ribonucleic acid (rna) market size has grown exponentially in recent years. It will grow from $18.86 billion in 2025 to $22.69 billion in 2026 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to advancements in molecular biology research, rising prevalence of genetic and chronic diseases, early success of rna-based therapeutics, increased research funding in genomics, establishment of rna interference mechanisms.

The small interfering ribonucleic acid (rna) market size is expected to see exponential growth in the next few years. It will grow to $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, growing demand for personalized medicine, expansion of nanoparticle delivery innovations, rising investments by pharmaceutical companies, broader application of sirna in infectious and rare diseases. Major trends in the forecast period include increasing clinical adoption of rna interference therapies, growing focus on targeted gene silencing approaches, expansion of advanced sirna delivery platforms, rising investment in precision therapeutics development, enhanced emphasis on scalable rna manufacturing.

The increasing demand for personalized medicine is anticipated to drive the growth of the small interfering ribonucleic acid (RNA) market in the coming years. Personalized medicine is a medical strategy that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The demand for personalized medicine is rising due to advances in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored treatments for patients. Small interfering ribonucleic acid (siRNA) supports personalized medicine by enabling precise gene silencing, making it effective for treating specific genetic disorders and diseases. It minimizes off-target effects by selectively inhibiting disease-causing mRNA, thereby improving therapeutic efficacy and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the small interfering ribonucleic acid (RNA) market.

Major companies operating in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on obtaining regulatory approvals for innovative mechanisms to treat rare genetic disorders, aiming to provide long-lasting effects and minimize dosing frequency for patients. Regulatory approvals are official authorizations from authorities permitting a drug or therapy to be safely tested, marketed, or administered to patients. For example, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. The therapy is designed to reduce antithrombin levels, thereby increasing thrombin generation to support clot formation and decrease bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing schedule, offering a novel, non-factor therapeutic option for hemophilia management.

In May 2025, AbbVie Inc., a US-based biopharmaceutical company, formed a partnership with ADARx Pharmaceuticals Inc. Through this collaboration, AbbVie Inc. aims to combine ADARx Pharmaceuticals Inc.'s proprietary RNA technology with its scientific expertise to develop next-generation small interfering RNA (siRNA) therapies, advancing progress in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company focused on developing small interfering ribonucleic acid (siRNA)-based therapies that target specific mRNA to treat diseases.

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small interfering ribonucleic acid (rna) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Interfering Ribonucleic Acid (RNA) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses small interfering ribonucleic acid (rna) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small interfering ribonucleic acid (rna) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small interfering ribonucleic acid (rna) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Liposome Systemic Therapy; Nanoparticle-Based Systemic Therapy
  • 2) By Indication: Cardiovascular Diseases; Respiratory Diseases; Oncology; Neurodegenerative Diseases; Infectious Diseases
  • 3) By End-User: Hospital; Research Institutions; Pharmaceutical And Biotechnology Companies; Academic Institutions
  • Subsegments:
  • 1) By Liposome Systemic Therapy: Cationic Liposome Delivery; Neutral Liposome Delivery; Pegylated Liposome Delivery; Targeted Liposome Delivery
  • 2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery; Polymer Nanoparticle Delivery; Gold Nanoparticle Delivery; Silica Nanoparticle Delivery
  • Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Sanofi S.A.; Sarepta Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Silence Therapeutics plc; Arrowhead Pharmaceuticals Inc.; Quark Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Evox Therapeutics Ltd.; Phio Pharmaceuticals Inc.; Genecon Biotechnologies Co. Ltd.; Olix Pharmaceuticals Inc.; Benitec Biopharma Ltd.; Bio-Path Holdings Inc.; Calando Pharmaceuticals Inc.; Sirnaomics Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Small Interfering Ribonucleic Acid (RNA) Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Small Interfering Ribonucleic Acid (RNA) Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Small Interfering Ribonucleic Acid (RNA) Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Small Interfering Ribonucleic Acid (RNA) Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Increasing Clinical Adoption Of RNA Interference Therapies
    • 4.2.2 Growing Focus On Targeted Gene Silencing Approaches
    • 4.2.3 Expansion Of Advanced siRNA Delivery Platforms
    • 4.2.4 Rising Investment In Precision Therapeutics Development
    • 4.2.5 Enhanced Emphasis On Scalable RNA Manufacturing

5. Small Interfering Ribonucleic Acid (RNA) Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Research Institutions
  • 5.3 Pharmaceutical Companies
  • 5.4 Biotechnology Companies
  • 5.5 Academic Institutions

6. Small Interfering Ribonucleic Acid (RNA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Small Interfering Ribonucleic Acid (RNA) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Small Interfering Ribonucleic Acid (RNA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Small Interfering Ribonucleic Acid (RNA) Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Small Interfering Ribonucleic Acid (RNA) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Small Interfering Ribonucleic Acid (RNA) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Small Interfering Ribonucleic Acid (RNA) Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Small Interfering Ribonucleic Acid (RNA) Market Segmentation

  • 9.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
  • 9.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
  • 9.3. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
  • 9.4. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Liposome Systemic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
  • 9.5. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Nanoparticle-Based Systemic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery

10. Small Interfering Ribonucleic Acid (RNA) Market Regional And Country Analysis

  • 10.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market

  • 11.1. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Small Interfering Ribonucleic Acid (RNA) Market

  • 12.1. China Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Small Interfering Ribonucleic Acid (RNA) Market

  • 13.1. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Small Interfering Ribonucleic Acid (RNA) Market

  • 14.1. Japan Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Small Interfering Ribonucleic Acid (RNA) Market

  • 15.1. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Small Interfering Ribonucleic Acid (RNA) Market

  • 16.1. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Small Interfering Ribonucleic Acid (RNA) Market

  • 17.1. South Korea Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Small Interfering Ribonucleic Acid (RNA) Market

  • 18.1. Taiwan Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Small Interfering Ribonucleic Acid (RNA) Market

  • 19.1. South East Asia Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Small Interfering Ribonucleic Acid (RNA) Market

  • 20.1. Western Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Small Interfering Ribonucleic Acid (RNA) Market

  • 21.1. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Small Interfering Ribonucleic Acid (RNA) Market

  • 22.1. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Small Interfering Ribonucleic Acid (RNA) Market

  • 23.1. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Small Interfering Ribonucleic Acid (RNA) Market

  • 24.1. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Small Interfering Ribonucleic Acid (RNA) Market

  • 25.1. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market

  • 26.1. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Small Interfering Ribonucleic Acid (RNA) Market

  • 27.1. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Small Interfering Ribonucleic Acid (RNA) Market

  • 28.1. North America Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Small Interfering Ribonucleic Acid (RNA) Market

  • 29.1. USA Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Small Interfering Ribonucleic Acid (RNA) Market

  • 30.1. Canada Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Small Interfering Ribonucleic Acid (RNA) Market

  • 31.1. South America Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Small Interfering Ribonucleic Acid (RNA) Market

  • 32.1. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Small Interfering Ribonucleic Acid (RNA) Market

  • 33.1. Middle East Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Small Interfering Ribonucleic Acid (RNA) Market

  • 34.1. Africa Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Small Interfering Ribonucleic Acid (RNA) Market Regulatory and Investment Landscape

36. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Company Profiles

  • 36.1. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Small Interfering Ribonucleic Acid (RNA) Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Small Interfering Ribonucleic Acid (RNA) Market Company Profiles
    • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Small Interfering Ribonucleic Acid (RNA) Market Other Major And Innovative Companies

  • Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

38. Global Small Interfering Ribonucleic Acid (RNA) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Small Interfering Ribonucleic Acid (RNA) Market

40. Small Interfering Ribonucleic Acid (RNA) Market High Potential Countries, Segments and Strategies

  • 40.1 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer